Skip to main content
Clinical Trials/IRCT20220416054548N1
IRCT20220416054548N1
Recruiting
Phase 2

Determining the association of response rate to Intravitreal injection of bevacizumab and macular vessel density in patients with diabetic macular edema using optical coherence tomography angiography (OCT-A) in outpatients referred to Feyz Hospital

Esfahan University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Esfahan University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age over 18 years
  • Having type 1 or 2 diabetes
  • Central macular edema based on Heidelberg's clinical examination and OCT in one or both eyes (at least 305 µm in women and 320 µm in men)
  • Best modified view less than or equal to 10/7
  • No history of laser in the patient's eye
  • Moderate to severe non\-proliferative diabetic retinopathy with diabetic macular edema
  • Transparent media to the extent that it does not interfere with the quality of images and their analysis (SSI: signal strength index: 37\-40\)

Exclusion Criteria

  • History of retinal vascular obstructive diseases
  • History of intraocular injection in the last 6 months
  • History of intraocular and retinal laser in the affected eye in the last 12 months
  • Decreased vision following any ocular pathology other than diabetic retinopathy
  • High Myopia (\= \-8\)
  • History of eye surgery in the last 6 months
  • Uncontrolled glaucoma (IOP \= 30 mmHg despite maximal treatment)
  • Uncontrolled diabetes
  • Uncontrolled blood pressure (SBP \=180 mmHg or DBP \=100 mmHg
  • Connective tissue diseases

Outcomes

Primary Outcomes

Not specified

Similar Trials